TBI-166

• UNSPSC Description:

  TBI-166, a riminophenazine analogue, is an orally active anti-tuberculosis agent with fewer adverse reactions than the lead riminophenazine compound, Clofazimine (HY-B1046) [1][2][3].

• Target Antigen:

  Bacterial

• Type:

  Reference compound

• Related Pathways:

  Anti-infection

• Applications:

  COVID-19-immunoregulation

• Field of Research:

  Infection

• Assay Protocol:

  https://www.medchemexpress.com/tbi-166.html

• Solubility:

  DMSO : 9.09 mg/mL (ultrasonic;adjust pH to 3 with HCl)

• Smiles:

  FC(F)(F)OC1=CC=C(N2C3=C/C(C(NC4=CC=CN=C4OC)=CC3=NC5=C2C=CC=C5)=N/C6CCC(OC)CC6)C=C1

• Molecular Weight:

  589.61

• References & Citations:

  [1]Xu J, et al. In Vitro and In Vivo Activities of the Riminophenazine TBI-166 against Mycobacterium tuberculosis. Antimicrob Agents Chemother. 2019 Apr 25;63(5):e02155-18. |[2]Zhu H, et al. Activity of Clofazimine and TBI-166 against Mycobacterium tuberculosis in Different Administration Intervals in Mouse Tuberculosis Models. Antimicrob Agents Chemother. 2021 Mar 18;65(4):e02164-20. |[3]Ding Y, et al. Superior Efficacy of a TBI-166, Bedaquiline, and Pyrazinamide Combination Regimen in a Murine Model of Tuberculosis. Antimicrob Agents Chemother. 2022 Sep 20;66(9):e0065822.

• Shipping Conditions:

  Room Temperature

• Clinical Information:

  Phase 2

• CAS Number:

  1353734-12-9